News

08.04.22 Medannex’s first-in-class agent shows significant activity against clinically challenging cancers
21.01.22 Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models
10.12.21 Medannex’s new therapy shows powerful synergy with common cancer treatments
10.09.21 Medannex team leads the field in BIA charity fundraiser
15.04.21 Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021
25.03.21 Medannex sweeps the board at Scotland’s Life Sciences Annual Awards
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. 6